JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

Eugène van Puijenbroek, Andrew Bate, Hubert G.M. Leufkens et al. · Pharmacoepidemiology and Drug Safety · 2002 · 1.3K citations

Pharmacy, Pharmacology, Clinical Pharmacology +16

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology

Julien Bezin, Mai Duong, R. Lassalle et al. · Pharmacoepidemiology and Drug Safety · 2017 · 560 citations

Public Affairs, Biomedical Informatics, Clinical Classification Systems +12

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy · 2019 · 320 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Case–non-case studies: Principle, methods, bias and interpretation

Jean‐Luc Faillie · Therapies · 2019 · 318 citations

Public Health, Biostatistics, Causal Inference +9